Molecular Partners (MOLN) and Orano Med said Tuesday that the latest preclinical data on their MP0712 product candidate confirmed "high tumor uptake" while keeping low kidney exposure.
The companies co-developed MP0712 as a radio-designed ankyrin repeat protein therapeutic candidate that targets delta-like ligand 3, according to the statement.
Molecular Partners and Orano Med said the latest data showed strong uptake by the targeted tissue, with minimal impact on health tissues. Dose-range finding studies in mice also confirmed that the treatment was well tolerated at relevant dosage.
The companies said they plan to start first-in-human studies in 2025, with initial clinical data on MP0712 expected within the same year.
Molecular Partners shares were up over 10% premarket.
Price: 7.47, Change: +0.69, Percent Change: +10.18
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。